Merck & Co., Inc. $MRK Shares Bought by Haven Private LLC

Haven Private LLC grew its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 47.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,311 shares of the company’s stock after acquiring an additional 1,063 shares during the period. Haven Private LLC’s holdings in Merck & Co., Inc. were worth $262,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Peoples Financial Services CORP. grew its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. Peoples Financial Services CORP. now owns 22,778 shares of the company’s stock valued at $1,803,000 after acquiring an additional 122 shares in the last quarter. McLean Asset Management Corp grew its stake in Merck & Co., Inc. by 3.7% in the second quarter. McLean Asset Management Corp now owns 3,543 shares of the company’s stock worth $292,000 after purchasing an additional 125 shares in the last quarter. Cora Capital Advisors LLC grew its stake in Merck & Co., Inc. by 2.4% in the second quarter. Cora Capital Advisors LLC now owns 5,343 shares of the company’s stock worth $423,000 after purchasing an additional 125 shares in the last quarter. Saiph Capital LLC grew its stake in Merck & Co., Inc. by 3.7% in the first quarter. Saiph Capital LLC now owns 3,565 shares of the company’s stock worth $320,000 after purchasing an additional 128 shares in the last quarter. Finally, Physician Wealth Advisors Inc. grew its stake in Merck & Co., Inc. by 2.9% in the second quarter. Physician Wealth Advisors Inc. now owns 4,587 shares of the company’s stock worth $363,000 after purchasing an additional 128 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

Shares of MRK stock opened at $86.15 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The business has a 50 day moving average of $84.57 and a two-hundred day moving average of $81.80. Merck & Co., Inc. has a 52 week low of $73.31 and a 52 week high of $105.07. The company has a market cap of $215.17 billion, a P/E ratio of 13.27, a PEG ratio of 0.95 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, October 30th. The company reported $2.58 EPS for the quarter, beating analysts’ consensus estimates of $2.36 by $0.22. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%.The company had revenue of $17.28 billion during the quarter, compared to the consensus estimate of $17 billion. During the same period in the previous year, the firm posted $1.57 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 3.7% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2025 guidance at 8.930-8.980 EPS. As a group, analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on MRK shares. Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Berenberg Bank downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research note on Wednesday, October 8th. Morgan Stanley decreased their price target on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Finally, Citigroup began coverage on Merck & Co., Inc. in a research note on Monday, October 13th. They issued a “neutral” rating and a $95.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $104.33.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.